Key terms
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NBIX news
Today
8:00am ET
Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Ultragenyx Pharmaceutical (RARE)
Apr 09
12:30am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
Apr 08
4:31am ET
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Neurocrine (NBIX)
Apr 03
5:16am ET
Wells Fargo Reaffirms Their Hold Rating on Neurocrine (NBIX)
Mar 28
8:31am ET
Neurocrine initiates Phase 1 study of NBI-1065890
Mar 20
7:03am ET
Neurocrine price target raised to $158 from $148 at JPMorgan
Mar 14
7:15am ET
Maintaining Hold Rating for Neurocrine Biosciences Amid Reduced Competition and Long-Term Market Potential
Mar 14
7:15am ET
Strong Buy on Neurocrine Biosciences as Crinecerfont Leads in CAH Market, Backed by Solid Pipeline and Underappreciated Value
Mar 14
6:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)
Mar 13
7:23am ET
Neurocrine price target raised to $200 from $170 at Oppenheimer
Mar 01
8:40am ET
Analysts Are Bullish on These Healthcare Stocks: Tenet Healthcare (THC), Moderna (MRNA)
Feb 26
7:16am ET
Voyager Therapeutics reports selection of gene therapy development candidate
Feb 23
11:55am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 23
11:00am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 22
7:32am ET
RBC Capital Keeps Their Hold Rating on Neurocrine (NBIX)
Feb 20
7:31am ET
Neurocrine price target raised to $159 from $128 at UBS
Feb 13
5:41am ET
Positive Outlook for Neurocrine Biosciences with Underappreciated Pipeline Potential
Feb 12
7:57am ET
Neurocrine price target raised to $164 from $157 at Guggenheim
Feb 09
12:56am ET
Neurocrine Biosciences: A Strong Buy on Robust Financial Performance and Promising Drug Pipeline
Feb 09
12:51am ET
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Sarepta Therapeutics (SRPT) and Neurocrine (NBIX)
Feb 08
8:59am ET
Neurocrine price target raised to $161 from $160 at Deutsche Bank
Feb 08
7:50am ET
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL)
Feb 08
7:48am ET
Oppenheimer Keeps Their Buy Rating on Neurocrine (NBIX)
Feb 08
7:33am ET
Neurocrine price target raised to $106 from $100 at Piper Sandler
Feb 08
7:31am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS) and Neurocrine (NBIX)
Feb 08
7:17am ET
Neurocrine price target raised to $154 from $150 at Canaccord
Feb 08
6:46am ET
Neurocrine price target raised to $140 from $116 at Mizuho
Feb 08
6:31am ET
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Arcus Biosciences (RCUS) and Neurocrine (NBIX)
Feb 08
6:27am ET
Neurocrine (NBIX) Gets a Buy from Barclays
Feb 08
6:17am ET
Neurocrine price target raised to $140 from $127 at Wells Fargo
Feb 08
6:16am ET
Promising Pipeline and Market Positioning Underpin Buy Rating for Neurocrine’s Stock (NBIX)
No recent news articles are available for NBIX
No recent press releases are available for NBIX
NBIX Financials
Key terms
Ad Feedback
NBIX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NBIX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
